CORONA Remedies Partners with Ferring Pharmaceuticals To commercialize Maternal Health & Urology products

To commercialise distinctive and ground-breaking products in the areas of Maternal Health & Urology, CORONA Remedies Private Limited (CORONA) has entered into an agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a subsidiary of global biopharmaceuticals company Ferring Pharmaceuticals with headquarters in Switzerland. The partnership between CORONA and Ferring will provide patients all over India with cutting-edge products, some of which will be from international brands, to meet the unmet treatment requirements in urology and maternal health.

"We are delighted to partner with Ferring, a research-driven, specialty biopharmaceutical group to bring world-class medicines to patients in India. This partnership is in sync with our purpose and commitment of #GoodHealthForAll," said Nirav Mehta, Promoter & Executive Director of CORONA. CORONA is one of the top names in women's healthcare and is well-known for its work in a number of therapeutic areas, including those involving the treatment of hypertension, diabetes, neuropathy, hormones, neuropathy, dermatology, bone health, ulcers, and nutritional supplements.

Numerous nations recognise Ferring's maternal health products, which are supported by clinical trials that show their efficacy and safety. Based on Ferring's new patented technology platform, the urology treatments are designed in an inventive dose form that will be very convenient for patients with overactive bladder and erectile dysfunction. All of the medications are distinct in their class and have distinct drug delivery technologies and formulations that provide therapeutic benefits in addition to patient compliance and convenience. The anticipated market size for all of the aforementioned products is Rs. 778.30 crore, and it is expanding by 27%.

More than 1500 CORONA Remedies authorised stockists will distribute the unique goods across the nation. A first-generation businessperson started CORONA Remedies Private Limited with the goal of enhancing everyone's level of health. With a ranking of 33rd in the Indian Pharmaceutical Market, CORONA is the youngest and fastest-growing company in the top 40, and it has a revenue of Rs 1063 crore, representing an 18% growth.